Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1239 studies found for:    "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
1 Completed A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
Condition: Carcinoma, Hepatocellular
Intervention: Biological: GV1001
2 Recruiting SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE
Condition: Carcinoma, Hepatocellular
Intervention: Radiation: SBRT
3 Enrolling by invitation Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Device: Arsenic trioxide TACE;   Drug: Arsenic trioxide intravenous infusion;   Drug: lipiodol;   Drug: NaCl solution
4 Completed Proteomic Analysis of Human Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Procedure: Operation
5 Completed TK-based Suicide Gene Therapy for Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Genetic: TK99UN
6 Completed Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib and Gemcitabine
7 Completed Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Somatostatin (octreotide)
8 Completed Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
9 Unknown  Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone
Condition: Carcinoma, Hepatocellular
Intervention: Procedure: percutaneous ethanol instillation (PEI)
10 Terminated Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Thalidomide(Thado)
11 Recruiting Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Procedure: Transarterial Chemoembolization;   Radiation: Proton Beam Radiotherapy
12 Recruiting Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton Beam Radiotherapy;   Drug: Sorafenib
13 Completed
Has Results
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Vandetanib;   Drug: Best Supportive Care
14 Recruiting Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: JNJ-42756493 (erdafitinib)
15 Unknown  Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: epirubicin;   Drug: Cisplatin
16 Completed Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
17 Recruiting Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Doxorubicin;   Drug: Best Standard of Care
18 Completed Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
19 Completed
Has Results
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
20 Recruiting Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: MSC2156119J;   Drug: Sorafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.